Navigation Links
Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
Date:4/16/2008

CHICAGO, April 16 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that it has regained compliance with the Nasdaq Capital Market listing requirements. On April 16, 2008, the Company received notification from the Nasdaq Listing Qualification Department that it has regained compliance with Nasdaq Marketplace Rule 4310(c)(4) because the closing bid price of the Company's common stock has been equal to or in excess of $1.00 for a minimum of ten consecutive business days.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired pneumonia (CAP). For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
2. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
3. Advanced Life Sciences Receives Nasdaq Notification
4. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
7. Advanced Medical Specialties Joins US Oncology Network
8. Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development
9. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
10. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
11. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/21/2017)... BOULDER, Colo. , Jan. 20, 2017 ... ("Bioptix" or the "Company"), announced that on January 14, ... a plan under which the Company will terminate certain ... subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on ... completed within 30 days.  The Company may pay severance ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):